| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T6 |
0-8 |
Sentence |
denotes |
ABSTRACT |
| T7 |
9-326 |
Sentence |
denotes |
The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. |
| T8 |
327-418 |
Sentence |
denotes |
COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors. |
| T9 |
419-572 |
Sentence |
denotes |
We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. |
| T10 |
573-737 |
Sentence |
denotes |
In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs. |
| T11 |
738-901 |
Sentence |
denotes |
This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension. |
